Apr 15, 2020
Invitation to Presentation of BioArctic's Interim Report for the First Quarter 2020 on April 22 at 9.30 a.m. CET
Dec 17, 2019
BioArctic Announces Research Collaboration with Eisai Regarding BAN2401
Dec 05, 2019
BioArctic's Partner Eisai Presents Data from the Ongoing BAN2401 Phase 2b Extension Study in Early Alzheimer's Disease
Dec 02, 2019
BioArctic and Eisai to Present Data on BAN2401 at the Clinical Trials on Alzheimer's Disease Conference
Jul 18, 2019
BioArctic and Eisai Present New Data Regarding BAN2401 at the Alzheimer's Association International Conference 2019
Jul 15, 2019
BioArctic's Co-Founder Received AAIC Lifetime Achievement Award
Jul 11, 2019
BioArctic and Eisai to Present BAN2401 at the Alzheimer's Association International Conference 2019
May 20, 2019
BioArctic Receives MEUR 15 Milestone Payment from Eisai for Start of BAN2401 Confirmatory Phase 3 Study in Early Alzheimer's Disease
May 10, 2019
BioArctic: Alzheimer's Clinical Trials Consortium and Eisai Announce BAN2401 to be Evaluated in Clinical Study for Prevention of Alzheimer's Disease
Mar 22, 2019
Initiation Of Phase III Clinical Trial Of BAN2401 In Early Alzheimer's Disease
Mar 21, 2019
BioArctic's Partner Eisai Initiates the Confirmatory Phase 3 Study of BAN2401 in Early Alzheimer's Disease
Mar 13, 2019
BioArctic Announces Start of Phase 1 Study of ABBV-0805 for Parkinson's Disease
Mar 07, 2019
BioArctic: Eisai Announces Timelines for the Single Confirmatory Phase 3 Study With BAN2401 in Warly Alzheimer's Disease
Feb 14, 2019
BioArctic - Full Year Report January - December 2018
Oct 25, 2018
BioArctic Announces Additional BAN2401 Phase 2b Study Results in Early Alzheimer's Disease Presented by Eisai at the 2018 CTAD Conference
Oct 21, 2018
BioArctic is Granted a Concept Patent in Europe for the Company's Strategy for Disease-modifying Treatment of Parkinson's Disease
Sep 13, 2018
BioArctic SIgns a Research Agreement With Brain Biomarker Solutions in Gothenburg AB to Develop New Diagnostics for Alzheimer's Disease
Aug 07, 2018
BioArctic Obtains Exclusive Rights to Develop Antibody Treatments for Alzheimer's Disease from a Research Project Jointly Owned with Eisai
Jul 25, 2018
Eisai And Biogen Announce Detailed Results Of Phase II Clinical Study Of BAN2401 In Early Alzheimer's Disease At Alzheimer's Association International Conference (AAIC) 2018
Jul 18, 2018
BioArctic: Late Breaking Phase 2b Study Results of BAN2401 in Alzheimer's Disease Will be Webcast Live From AAIC 2018 by Eisai